|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Alterations characteristic of adenocarcinoma (EGFR, KRAS, ALK receptor tyrosine kinase [ALK], ROS1, and serine/threonine kinase 11 [STK11]) were detected in the LCC-AD subgroup but not in LCC-SqCC, whereas squamous-lineage alterations (phosphatidylinositol-4,5-biphosphate 3-kinase catalytic subunit alpha [PIK3CA], SRY-box 2 [SOX2], fibroblast growth factor receptor 1 [FGFR1], and AKT1) were detected in the LCC-SqCC subgroup but not in the LCC-AD group.
|
30978501 |
2019 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Here, we demonstrate lineage switching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion of Lkb1 (Stk11) in autochthonous and transplant models.
|
28387316 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the liver kinase B1 (official name STK11)-deficient mouse model, lung ADC can progressively transdifferentiate to SCC through pathologically mixed adenosquamous cell carcinoma as the intermediate status.
|
28284717 |
2017 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, within the BRAF inhibitor-associated group, the lesions designated as KAs and BRAF inhibitor-associated verrucous keratoses had a similar mutational profile (mutations in PIK3CA, APC, and HRAS), which was distinct to that seen in squamous cell carcinomas (FGFR3, CDKN2A, and STK11).
|
26319365 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrate that phenformin in combination with MLN0128 induced a significant therapeutic response in KRAS/LKB1-mutant human cell lines and genetically engineered mouse models of NSCLC that develop both adenocarcinomas and SCCs.
|
26574479 |
2015 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Here we show that YAP, the major effector of the Hippo pathway, displays a distinct activation pattern in lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC); YAP is initially activated by LKB1 loss in lung ADC, which upregulates ZEB2 expression and represses DNp63 transcription in a default manner.
|
25115923 |
2014 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the squamous cell carcinoma (SCC) cell lines SCC9 and SCC25, lovastatin treatment (1-25 µM, 24 hrs) induced LKB1 and AMPK activation similar to metformin (1-10 mM, 24 hrs), a known inducer of this pathway.
|
23029387 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PTEN (16.1%), STK11 (8.3%), and PIK3CA (7.2%) were the three most frequently enriched genes in smokers with SCC.
|
22768234 |
2012 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients.
|
18594528 |
2008 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
LHGDN |
Deletions of N33, STK11 and TP53 are involved in the development of lymph node metastasis in larynx and pharynx carcinomas.
|
17641416 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively.
|
17676035 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively.
|
17676035 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively.
|
17676035 |
2007 |
|
Squamous cell carcinoma
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
A novel mutation of STK11/LKB1 gene leads to the loss of cell growth inhibition in head and neck squamous cell carcinoma.
|
16407837 |
2006 |